Evolus plunges after Q2 miss, guidance cut; Needham downgrades
Source: SeekingAlpha
2025-08-06 15:31:08 ET
More on Evolus
- Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
- Evolus, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
- Evolus outlines $700M 2028 revenue target and cost realignment amid market softness
- Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M
Read the full article on Seeking Alpha
For further details see:
Evolus plunges after Q2 miss, guidance cut; Needham downgrades
AbbVie Inc.
NASDAQ: ABBV
ABBV Trading
0.21% G/L:
$228.2209 Last:
2,045,501 Volume:
$226.05 Open:
ABBV Latest News
ABBV Stock Data
$396,361,630,803
1,749,710,786
N/A
2503
N/A
Pharmaceuticals
Healthcare
US
North Chicago
